| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Department of Medicine and the Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637
| ABSTRACT |
|---|
|
|
|---|
-radiation. Among the genes identified in this screen were several that regulate glycolytic metabolism. Enzymes that catalyze key regulatory steps of glycolysis, including hexokinase, phosphofructokinase, and pyruvate kinase, appeared to be coordinately down-regulated by genotoxic exposure. Northern blotting confirmed that these changes in gene expression occur within 4 h of exposure to several DNA-damaging agents. Genotoxic exposure was found to similarly inhibit expression of both glut-1 and glut-3, genes that encode critical regulators of glucose uptake. Direct measurement of glycolytic rate and of oxygen consumption confirmed that genotoxic exposure resulted in suppression of both anaerobic and aerobic metabolism. Many of these metabolic changes mimic those observed after growth factor withdrawal. Together, these observations suggest that multiple apoptotic triggers, including growth factor withdrawal and genotoxic exposure, suppress cellular bioenergetic pathways. Mitochondrial responses to the resulting rapid decrease in metabolic substrates may play an important role in initiation of apoptotic cell death. | INTRODUCTION |
|---|
|
|
|---|
The molecular pathways from DNA damage to apoptotic commitment are incompletely understood. Although the p53 protein plays a central role in coordinating many responses to DNA damage, p53-independent induction of apoptosis after DNA damage has also been reported in many systems (5 , 6) . Therapeutic resistance to DNA-damaging agents can derive from overexpression of genes encoding apoptotic resistance factors, such as Bcl-2 or Bcl-xL (7 , 8) . These Bcl-2 family members function in the outer membrane of mitochondria to inhibit the loss of mitochondrial homeostasis resulting in cytochrome c release and apoptotic initiation (9) . The nature of the signaling pathway from nuclear genomic damage to mitochondrial response has not been fully characterized.
Recent data have implicated changes in uptake and utilization of glucose in the mitochondrially dependent apoptotic pathway initiated by growth factor withdrawal (10) . Restriction of growth factor availability from lymphocytes in culture and in vivo results in progressive cellular atrophy and cell death. Cellular atrophy is most evident in cells in which the apoptotic response has been inhibited by overexpression of an antiapoptotic Bcl-2 family member (11) . Cellular atrophy is associated with down-regulated expression of the glut-1 gene, encoding a cell surface glucose uptake transporter, with decreased cellular ATP levels, and with rapid inhibition of expression of HK12 and PFK1, key regulators of glycolytic metabolism (10 , 11) . Growth factor receptor signaling may promote cell growth and survival in part by stimulating continued glucose uptake and glycolytic metabolism.
Down-regulation of glycolytic rate results in a decrease in the availability of substrates for oxidative phosphorylation. One of the functions of antiapoptotic Bcl-2 family members appears to be maintenance of ATP/ADP exchange across the mitochondrial membrane under conditions of stress, including growth factor withdrawal (12) . Growth factor withdrawal in IL-3-dependent cells leads to a deficiency in the ability to exchange mitochondrial ATP for cytoplasmic ADP, with subsequent mitochondrial swelling, loss of mitochondrial membrane potential, and loss of outer mitochondrial membrane integrity. Bcl-xL expression can maintain mitochondrial ATP/ADP exchange and prevent the subsequent alterations associated with the induction of programmed cell death (12) . Maintenance of adenine nucleotide exchange by Bcl-xL may facilitate integration of cytoplasmic (glycolytic) and mitochondrial (oxidative) metabolism. This continued integration may be critical in preventing mitochondrial alterations associated with the initiation of programmed cell death after rapid decreases in the rate of glycolysis.
Whether suppression of glycolytic metabolism is associated only with extrinsic apoptotic induction, such as mediated by growth factor withdrawal, or represents part of a more general apoptotic response has not been determined. In particular, the changes in bioenergetic regulation initiated by genotoxic damage, and their association with apoptotic induction, have not been characterized. We initiated a screen to identify changes in gene expression after exposure to cisplatin, a potent genotoxic agent, by subtractive suppressive hybridization. Among the many differentially expressed transcripts identified as either up-regulated or down-regulated after cisplatin exposure were a number involved in the regulation of glycolytic metabolism. Here we report that exposure to multiple DNA-damaging agents is associated with marked down-regulation of cellular bioenergetic pathways, with inhibition of expression of genes encoding rate-limiting factors in glycolysis and factors responsible for glucose uptake by cells. Many of these effects appear to parallel metabolic alterations observed on apoptotic induction by growth factor withdrawal, suggesting a common bioenergetic response pathway.
| MATERIALS AND METHODS |
|---|
|
|
|---|
radiation was delivered from a single cesium source emitting 2.86 Gy/min.
Centrifugal Elutriation.
Elutriation was performed using a JE-6B elutriation system (Beckman Instruments) according to the manufacturers instructions. FL5.Bcl-xL cells (5 x 108) were loaded into the centrifuge at a rotor speed of 3200 rpm and a flow rate of 25 ml/min. Rotor speed was decreased in 100 rpm increments, and 50-ml fractions were collected at each interval. Fractions were split immediately for analysis of cell cycle profile and RNA preparation and for culture, either with or without 5 µg/ml cisplatin. Synchronized populations with or without cisplatin were used for RNA preparation and cell cycle analysis at time points
22 h after elutriation. RNA preparation was performed using TRIzol reagent (Life Technologies, Inc., Rockville, MD) according to the manufacturers instructions. Cell cycle analysis was performed by propidium iodide staining and flow cytometry as described previously (15)
.
Subtractive Suppressive Hybridization.
Subtractive suppressive hybridization was performed using the PCR-Select cDNA Subtraction Kit (Clontech, Palo Alto, CA) according to the manufacturers instructions. In brief, total cellular RNA from cisplatin-treated, G2 phase-arrested cells and untreated G2 phase cycling cells was used as a template for double-stranded cDNA synthesis. cDNA from cisplatin-treated and untreated cells was used as a tester and driver, respectively, to identify up-regulated genes and in the reverse arrangement, to identify down-regulated genes. Both cDNA populations were digested with RsaI, and tester cDNA was ligated to adapters 1 and 2 in two separate reactions. These ligated populations were heat denatured and hybridized with molar excess of denatured driver cDNA lacking adapters. The two hybridization reactions were then mixed, and PCR was performed using primers complementary to adapters 1 and 2. cDNAs over-represented in the tester population were further enriched by a second round of subtractive hybridization with excess driver cDNA.
Products of this initial screen were directly cloned into Topo-TA (Invitrogen, Carlsbad, CA) and transformed into Escherichia coli. Randomly selected batches of 96 colonies were inoculated onto a nylon membrane and lysed, and the DNA was fixed to the membrane. These membranes were then probed with 32P-labeled tester and driver cDNA, as well as with subtracted or reverse subtracted cDNA probes. Over 2000 clones were screened using this technique.
Northern Blotting.
Total cellular RNA was prepared using TRIzol reagent (Life Technologies, Inc.) according to the manufacturers instructions. Equal amounts of RNA, quantitated by spectrophotometry, were run on 1% agarose and blotted onto nitrocellulose. Blots were hybridized with 32P-labeled probes derived by random priming of DNA fragments or by polynucleotide kinase end-labeling for the 5S RNA oligonucleotide probe (5'aaagcctacagcacccggtat3'). The probe for pyruvate kinase was derived from the gene fragment cloned in the screen. Probes for glut-1, glut-3, HK1, HK2, PFK1, and
enolase were amplified from total cellular RNA by RT-PCR. The primers used included: 5'-gcggccatggatcccagcag-3' and 5'-acttggtgggagtccgcccccag-3' for glut-1, 5'-cctctggtccttatgtgtggccatctt-3' and 5'-ccgaccagaaagttggaggtccagtta-3' for glut-3, 5'-aaagatgttgcccacctacg-3' and 5'-gaagctgccatcctgctaac-3' for HK1, 5'-cctgcttattcacggagctcaaccaa-3' and 5'-cctgctccatttccaccttcatcctt-3' for HK2, 5'-atgaagagcatcatgcagccaaaacc-3' and 5'-tggttaccagagaggctcaccacaca-3' for PFK1, and 5'-ccgagacaatgataagacccgcttca-3' and 5'-gatctccggtccatgctttatttggc-3' for
-enolase. The 18S rRNA probe was purchased from Ambion, Inc. (Austin, TX).
Western Blotting.
Whole cell lysates were prepared in radioimmunoprecipitation assay buffer, and protein concentration was determined by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA). Samples normalized for protein content were run on 14% polyacrylamide gels (Invitrogen) and electrophoretically transferred to nitrocellulose. Filters were probed sequentially with anti-Glut-1 antibody sc-7903 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-Glut-3 antibody sc-7582 (Santa Cruz Biotechnology), and anti-ß-actin antibody AC-15 (Sigma, St. Louis, MO). Blots were developed using an enhanced chemiluminescence kit (Amersham/Pharmacia) according to the manufacturers instructions.
Measurement of Glycolytic Rate.
Determination of glycolytic rate was dependent on the conversion of 5-3H-glucose to 3H2O, as described previously (10
, 16)
. Synthesis of radiolabeled H2O is dependent on conversion of 2-phosphoglycerate to phophoenolpyruvate in the glycolytic pathway. Briefly, 1 x 106 cells were washed and resuspended in 500 µl of Krebs buffer [25 nM NaHCO3, 115 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mM MgCl2, and 0.25% BSA (pH 7.4)] for 30 min in 5% CO2 at 37°C. Cells were then pelleted and resuspended in 500 µl of Krebs buffer containing 1 mM glucose and 10 µCi 5-3H-glucose for 60 min in the same conditions. Aliquots (100 µl) of each sample were added to 50 ml of 0.2 N HCl in open 500-ml centrifuge tubes. These tubes were placed upright in scintillation vials containing 1 ml H2O. The vials were sealed and permitted to equilibrate for
24 h at room temperature. The amount of 3H retained within the centrifuge tube and the amount that had diffused out by evaporation and condensation into the surrounding H2O were determined separately. 5-3H-glucose and 3H2O standards were included in each experiment, permitting the calculation of the rate of conversion in each experimental sample, as described previously (17)
. All experiments were performed in triplicate.
Measurement of Oxygen Consumption.
Aliquots of 4 x 106 cells in 4.5 ml of media were introduced into a functionally airtight Warburg chamber at 37°C, equipped with a polarographic O2 electrode. The rate of decline in oxygen tension in the closed system is directly proportional to cellular O2 consumption.
PO2 (torr)/
t (min) was continuously recorded over 10 min and was used to calculate respiratory rate as described previously (18)
. All experiments were performed in triplicate.
| RESULTS |
|---|
|
|
|---|
20 h (data not shown). To isolate RNA from cells shortly after cell cycle arrest, isolated G1 cells were exposed to 5 µg/ml cisplatin and cultured for 22 h (Fig. 1)
|
-enolase, pyruvate kinase, and lactate dehydrogenase, enzymes catalyzing the last three biochemical steps in cytoplasmic glycolysis. Pyruvate kinase, a rate-limiting regulator of glycolysis, drives the conversion of phosphoenolpyruvate to pyruvate, which can then be incorporated into acetyl-CoA, a substrate for the tricarboxylic acid cycle and subsequent oxidative degradation to CO2 and H2O in mitochondria. It was possible that the down-regulation of pyruvate kinase expression was unique to cisplatin exposure. However, Northern blotting demonstrates that this inhibition is found consistently with multiple DNA-damaging agents, including not only cross-linking agents, such as cisplatin, but also etoposide and
radiation, which induce double-strand breaks by distinct mechanisms (Fig. 2)
|
|
To evaluate whether the observed decrease in glucose transporter gene expression correlated with decreased protein level, Western blotting was performed using anti-Glut-1 and anti-Glut-3 antibodies. A decrease in both Glut-1 and Glut-3 protein levels was evident after exposure to cytotoxic agents or IL-3 withdrawal (Fig. 4)
. As expected, the decrease in protein levels occurred over a slower time course than the observed decrease in mRNA (compare Figs. 3
and 4
).
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Cytochrome c redistribution from the mitochondria to the cytosol has been implicated in the cell death pathway after multiple apoptotic stimuli, including both radiation and genotoxic drugs (19) . Both cytochrome c redistribution and apoptosis are prevented by Bcl-2 protein expression (19, 20, 21) . Bcl-2 proteins are thought to inhibit cell death at least in part through their ability to prevent mitochondrial dysfunction and cytochrome c release. Studies using other cell death triggers have shown that Bcl-2 proteins can prevent mitochondrial damage associated with apoptosis despite failing to inhibit upstream apoptotic signaling events, e.g., Bcl-xL prevents cytochrome c redistribution and promotes cellular viability despite having no effect on the metabolic arrest and progressive cellular atrophy that accompany growth factor withdrawal (11) . Similarly, our data suggest that in response to genotoxic damage, Bcl-xL is unable to prevent the initial metabolic consequences but is able to preserve mitochondrial integrity and inhibit apoptosis. Bcl-xL is present on the outer mitochondrial membrane and acts to maintain outer membrane permeability to metabolic anions (22 , 23) . An inability to continue mitochondrial ADP/ATP exchange results in a disruption of mitochondrial function and release of contents of the mitochondrial intermembrane space. Introduction of exogenous Bcl-xL results in preservation of mitochondrial adenine nucleotide exchange and prevents the other characteristic mitochondrial alterations associated with programmed cell death.
Cells overexpressing Bcl-xL were chosen for these experiments so that the metabolic alterations associated with genotoxic exposure could be examined without the confounding variable of cell death. It is possible that the changes observed in expression of genes encoding glycolytic regulatory factors and in metabolic rate are influenced directly or indirectly by the presence of the Bcl-xL gene. However, similar alterations in glycolytic regulatory genes have been noted after growth factor withdrawal in FL5.12 cells with or without Bcl-xL, suggesting that these changes are not dependent on exogenous expression of Bcl-xL (10) . The mechanism for the coordinated transcriptional inhibition of multiple genes controlling glycolytic metabolism is unknown. The observed suppression of these genes within hours of DNA damage or growth factor withdrawal suggests that the mechanism is more likely to be dependent on modified activity of extant factors within the cell rather than on new gene transcription and translation.
The change in glucose metabolism that occurs after genotoxic damage may result in the mitochondrial damage that leads to cytochrome c redistribution and apoptosis. Mitochondrial dysfunction and cell death after growth factor withdrawal is also preceded by a decrease in cellular glucose utilization (10) . Limitation of glucose utilization by nutrient availability alone results in mitochondrial dysfunction, cytochrome c redistribution, and apoptosis. Thus, the bioenergetic consequences of DNA damage identified here suggest that changes in glucose metabolism may be part of the common pathway that leads to mitochondrial dysfunction, cytochrome c redistribution, and the initiation of apoptosis.
Anaerobic metabolism in the cytosol is intimately linked to mitochondrial function. Oxidative phosphorylation and mitochondrial function are necessary for the efficient regeneration of NAD from NADH that is required for glycolysis to continue. Additionally, both pyruvate and reducing equivalents derived from glycolysis serve as the substrates that enable mitochondria to perform oxidative phosphorylation and regulate their own homeostasis. The majority of active processes carried out in mitochondria, including the control of mitochondrial volume homeostasis, requires the presence of a potential across the inner mitochondrial membrane (24 , 25) . When oxidative phosphorylation becomes limited, a resultant disruption in mitochondrial volume homeostasis has been proposed to be responsible for a loss of outer mitochondrial membrane integrity, cytochrome c redistribution, and the induction of apoptosis (21) .
A decreased ability to use glucose may be the point of integration that connects specific cellular stress responses to the apoptotic machinery through the mitochondria and cytochrome c. As in the case of growth factor withdrawal, we have found that DNA-damaging agents initiate a characteristic set of alterations in basic bioenergetic pathways, including decreased expression of the principal regulators of glucose uptake and glycolytic metabolism, as well as a functional down-regulation of both anaerobic and aerobic metabolism. The similarity in the metabolic effects of apoptotic initiation by growth factor withdrawal and by genotoxic exposure suggests that this response plays a central role in the cellular response to apoptotic initiation.
Maintenance of glycolytic metabolism is important not only to the preservation of ATP generation but also for the maintenance of the hexose monophosphate pathway, a critical generator of NADPH in the cell. Among other functions, NADPH is essential for the maintenance of reduced glutathione. Glutathione is a critical intracellular antioxidant and may protect cells against apoptotic cell death through the preservation of protein sulfhydryl groups in a reduced state (26) . Administration of bifunctional thiol-reactive agents, which mimic formation of covalent disulfide bridges, has been associated with apoptotic induction, whereas monofunctional thiol-reactive agents appear to have a protective function (27 , 28) .
The regulation of glucose utilization is complex, and the exact mechanism of glycolytic inhibition may vary between DNA damage, growth factor withdrawal, and other cell death-inducing stimuli. In addition to the transcriptional control of glucose transporters and glycolytic enzymes observed here, a variety of other mechanisms may disrupt glycolysis. Glucose transport into the cell is limited by the levels of various glucose transporters at the cell surface. Although some glucose transporters, such as Glut-1, appear to be controlled by the amount of transporter expressed, insulin-dependent glucose transport is regulated by the translocation of intracellular Glut-4 to the cell surface (29) . Intracellular trafficking may represent another means to regulate glucose utilization in response to apoptotic stimuli. Notably, glycolytic rate was significantly affected by vincristine exposure, despite relatively minimal effects on the expression of genes encoding regulators of glucose uptake and metabolism.
Glycolytic enzyme activity can also be regulated by post-translational mechanisms. The reaction catalyzed by PFK1 exerts the most control over the rate of glycolysis in mammalian cells. PFK1 enzyme activity is under complex allosteric regulation that involves cellular adenine nucleotide concentrations in addition to the levels of another metabolite, fructose-2,6-bisphosphate (30 , 31) . Fructose-2,6-bisphosphate levels are regulated by enzyme phosphorylation, indicating a target for regulation by cellular signal transduction pathways. Therefore, although genotoxic damage appears to affect bioenergetic pathways through altered expression of important metabolic genes, the cellular response to other agents may intersect the metabolic pathways differently, reflecting distinct upstream signal transduction. This hypothesis is supported by the observation that vincristine treatment resulted in an inhibition of metabolism similar to that observed after genotoxic damage and growth factor withdrawal, despite little evident change in metabolic gene expression.
The observation that decreased glucose utilization may represent a central pathway of apoptotic response has important implications for our understanding of cancer therapy. The great majority of neoplastic cells relies principally on glycolytic metabolism. Cancer cells maintain a high glycolytic rate despite the presence of adequate oxygen in their environment, a phenomenon known as the Warburg effect (32) . The transformation event leading to altered metabolism may have implications for the therapeutic sensitivity of a particular tumor. Differences in the mechanisms leading to altered glycolytic dependence in various tumors may differentially affect tumor sensitivity to various anticancer agents. Studies of neoplastic cells have identified altered expression of genes involved in glucose utilization (33, 34, 35) , and overexpression of genes involved in glucose utilization has been shown to inhibit cell death (10 , 23) . A better understanding of both how bioenergetic pathways are altered in specific neoplasms and how different agents inhibit metabolism and result in tumor cell death may lead to better targeting of and improved therapeutic response to antineoplastic regimens.
| FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Section of Hematology/Oncology, MC 2115, 5841 South Maryland Avenue, Chicago IL 60637. Phone: (773) 703-4142; Fax: (773) 702-0963; E-mail: crudin{at}medicine.bsd.uchicago.edu ![]()
2 The abbreviations used are: HK, hexokinase; IL, interleukin; PFK, phosphofructokinase. ![]()
Received 1/28/02. Accepted 4/15/02.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. J. Kominsky, J. Klawitter, J. L. Brown, L. G. Boros, J. V. Melo, S. G. Eckhardt, and N. J. Serkova Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells Clin. Cancer Res., May 15, 2009; 15(10): 3442 - 3450. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Schmidt, A Hommel, V Gawlik, R Augustin, N Junicke, S Florian, M Richter, D J Walther, D Montag, H-G Joost, et al. Essential role of glucose transporter GLUT3 for post-implantation embryonic development J. Endocrinol., January 1, 2009; 200(1): 23 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Sullivan Anatomic and Functional Imaging Techniques for Response Assessment in Oncology ASCO Educational Book, January 1, 2009; 2009(1): 119 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Huc, X. Tekpli, J. A. Holme, M. Rissel, A. Solhaug, C. Gardyn, G. Le Moigne, M. Gorria, M.-T. Dimanche-Boitrel, and D. Lagadic-Gossmann c-Jun NH2-Terminal Kinase-Related Na+/H+ Exchanger Isoform 1 Activation Controls Hexokinase II Expression in Benzo(a)Pyrene-Induced Apoptosis Cancer Res., February 15, 2007; 67(4): 1696 - 1705. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Engles, S. A. Quarless, E. Mambo, T. Ishimori, S. Y. Cho, and R. L. Wahl Stunning and Its Effect on 3H-FDG Uptake and Key Gene Expression in Breast Cancer Cells Undergoing Chemotherapy J. Nucl. Med., April 1, 2006; 47(4): 603 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. VanderWeele and C. M. Rudin Mammalian Target of Rapamycin Promotes Vincristine Resistance through Multiple Mechanisms Independent of Maintained Glycolytic Rate Mol. Cancer Res., November 1, 2005; 3(11): 635 - 644. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. VanderWeele, R. Zhou, and C. M. Rudin Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin Mol. Cancer Ther., December 1, 2004; 3(12): 1605 - 1613. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gottschalk, N. Anderson, C. Hainz, S. G. Eckhardt, and N. J. Serkova Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells Clin. Cancer Res., October 1, 2004; 10(19): 6661 - 6668. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |